Susan Bobulsky leads the clonoSEQ MRD clinical diagnostic testing business at Adaptive Biotechnologies. She brings 20 years of experience in biotechnology and diagnostics commercialization. Prior to her current role, Susan served in commercial and strategic planning roles of ascending responsibility at Adaptive. Before joining Adaptive, Susan was an associate partner with ZS Associates, a healthcare management consulting firm, where she specialized in commercialization strategy and execution for oncology therapeutic and diagnostic products. Susan holds an MBA from the Stanford Graduate School of Business and a BS in Science, Technology and Society from Stanford University.
Transforming Care for Lymphoid Cancer Patients Using MRD
We will discuss promising work in MRD: recent data, KOL perspectives, and how MRD transforms patient care.
Session Abstract – PMWC 2023 Silicon Valley
The PMWC 2023 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.
- Emerging Therapeutics/Cell Therapy
- Emerging Therapeutics/CVD
- Emerging Therapeutics/Gene Therapy
- Emerging Therapeutics/Immunotherapy
- Emerging Therapeutics/Radiation Therapy